Magnetic resonance elastography shear wave velocity correlates with liver fibrosis and hepatic venous pressure gradient in adults with advanced liver disease by Gharib, Ahmed M. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1155/2017/2067479
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Gharib, A. M., Han, M. A. T., Meissner, E. G., Kleiner, D. E., Zhao, X., McLaughlin, M., ... Morse, C. G. (2017).
Magnetic resonance elastography shear wave velocity correlates with liver fibrosis and hepatic venous pressure
gradient in adults with advanced liver disease. BioMed Research International, 2017, [2067479]. DOI:
10.1155/2017/2067479
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
Research Article
Magnetic Resonance Elastography Shear Wave Velocity
Correlates with Liver Fibrosis and Hepatic Venous Pressure
Gradient in Adults with Advanced Liver Disease
AhmedM. Gharib,1 Ma Ai Thanda Han,2 Eric G. Meissner,3,4,5
David E. Kleiner,6 Xiongce Zhao,7 Mary McLaughlin,3 Lindsay Matthews,3
Bisharah Rizvi,2 Khaled Z. Abd-Elmoniem,1 Ralph Sinkus,8 Elliot Levy,9
Christopher Koh,2 Robert P. Myers,10 G. Mani Subramanian,10 Shyam Kottilil,3
Theo Heller,2 Joseph A. Kovacs,4 and Caryn G. Morse4
1 National Institute of Diabetes and Digestive and Kidney Diseases, Biomedical and Metabolic Imaging Branch, Bethesda, MD, USA
2 National Institute of Diabetes and Digestive and Kidney Diseases, Liver Diseases Branch, Bethesda, MD, USA
3 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
4 Critical Care Medicine Department, NIH Clinical Center, AIDS Section, Bethesda, MD, USA
5 Division of Infectious Diseases, Department of Microbiology and Immunology, Medical University of South Carolina,
Charleston, SC, USA
6 Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
7 National Institute of Diabetes and Digestive and Kidney Diseases, Office of the Director, Bethesda, MD, USA
8 Biomedical Engineering, Imaging Sciences and Biomedical Engineering Division, Kings College, London, UK
9 Interventional Radiology, NIH Clinical Center, Bethesda, MD, USA
10Gilead Sciences, Inc., Foster City, CA, USA
Correspondence should be addressed to Caryn G. Morse; cmorse@cc.nih.gov
Received 10 January 2017; Accepted 20 March 2017; Published 5 April 2017
Academic Editor: Fernando Romeiro
Copyright © 2017 Ahmed M. Gharib et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Portal hypertension, an elevation in the hepatic venous pressure gradient (HVPG), can be used to monitor disease
progression and response to therapy in cirrhosis. Since obtaining HVPG measurements is invasive, reliable noninvasive methods
of assessing portal hypertension are needed.Methods.Noninvasive markers of fibrosis, including magnetic resonance elastography
(MRE) shear wave velocity, were correlated with histologic fibrosis and HVPG measurements in hepatitis C (HCV) and/or HIV-
infected patients with advanced liver disease enrolled in a clinical trial of treatment with simtuzumab, an anti-LOXL2 antibody.
Results. This exploratory analysis includes 23 subjects: 9 with HCV monoinfection, 9 with HIV and HCV, and 5 with HIV and
nonalcoholic steatohepatitis. Median Ishak fibrosis score was 4 (range 1–6); 11 subjects (48%) had cirrhosis. Median HVPG was
6mmHg (range 3–16). Liver stiffness measured by MRE correlated with HVPG (𝑟 = 0.64, 𝑝 = 0.01), histologic fibrosis score (𝑟 =
0.71, 𝑝 = 0.004), noninvasive fibrosis indices, including APRI (𝑟 = 0.81, 𝑝 < 0.001), and soluble LOXL2 (𝑟 = 0.82, 𝑝 = 0.001). On
stepwise multivariate regression analysis, MRE was the only variable independently associated with HVPG (𝑅2 = 0.377, 𝑝 = 0.02).
Conclusions.MRE of the liver correlated independently with HVPG. MRE is a valid noninvasive measure of liver disease severity
andmay prove to be a useful tool for noninvasive portal hypertension assessment. Trial Registration Number. This trial is registered
with NCT01707472.
1. Background
Chronic liver injury with progressive hepatic fibrosis can
result in cirrhosis, a leading cause of morbidity andmortality
worldwide [1]. Portal hypertension, defined as increased
pressure within the portal venous system, contributes to the
serious complications of end stage liver disease, including
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gastroesophageal varices and ascites. The established stan-
dard for diagnosing portal hypertension is transjugular mea-
surement of the hepatic venous portal gradient (HVPG),
the difference between wedged and free hepatic venous
pressures. HVPG measurements are utilized in managing
liver disease for prognostication, monitoring of progression,
and measuring response to therapy [2–5]. However, HVPG
measurements are invasive, costly, and often available only at
referral centers [6].
Identifying reliable noninvasive markers of portal hyper-
tension would improve clinical ability to determine disease
status and monitor fibrosis progression with reduced risk
compared with HVPG measurements. A number of labora-
tory tests and laboratory indices have been evaluated as non-
invasive markers of portal hypertension, including platelet
count, prothrombin time, and aspartate aminotransferase
platelet ratio (APRI); however these markers cannot reliably
predict the presence of varices or serve as surrogates for
HVPG [7].
Conventional imaging modalities have been used to
support a diagnosis of cirrhosis and portal hypertension but
have limited utility for confirming the presence of fibrosis or
for the longitudinal assessment of portal hypertension [8–
10]. Ultrasound-based vibration-controlled transient elastog-
raphy (VCTE; Fibroscan) can predict advanced fibrosis and
cirrhosis and correlates with HVPG [11]. Liver stiffness mea-
sured by VCTE predicts clinical decompensation and com-
plications of portal hypertension [12]. However, VCTE is lim-
ited by operator dependence, small sampling window, and
unreliability in patientswith abdominal obesity or ascites [13].
Magnetic resonance elastography (MRE) is now available
as an alternative method for determining liver stiffness. MRE
can accurately detect both early and advanced fibrosis [14]
and predict the presence of esophageal varices [15]. MRE
can be successfully performed in most patients, including
those with ascites, anatomical variants, and liver transplant
recipients [16]. The accuracy of MRE appears to be superior
to VCTE [17, 18], though the number of clinical studies
that compare the two methods is small. The use of MRE
of the liver in assessment of portal hypertension has been
explored in animal models [19]; however studies in humans
are limited to the detection of clinicalmanifestations of portal
hypertension, such as the development of esophageal varices
[20].
In this prospective, exploratory study, we assessed the
accuracy of noninvasive fibrosis biomarkers and MRE shear
wave velocity for the diagnosis of fibrosis and portal hyper-
tension in a cohort of hepatitis C (HCV) and/or human
immunodeficiency virus- (HIV-) infected liver disease pati-
ents. Participants were evaluated as part of a clinical trial
evaluating the safety and efficacy of simtuzumab (Gilead Sci-
ences, Inc., Foster City, CA), a humanized monoclonal anti-
body that inhibits lysyl oxidase-like 2 (LOXL2), an enzyme
that contributes to liver fibrosis by catalyzing collagen cross-
linkage.
2. Methods
2.1. Patient Population. Adults 18 years of age or older,
with HIV, HCV, or HIV/HCV, were enrolled from October
2012 to December 2014. HCV infection was confirmed by
measurement of HCVRNA >2,000 IU/mL. For HIV-infected
subjects, an HIV viral load <400 copies/mL on stable com-
bination antiretroviral therapy for ≥3 months was required.
Patients with known cirrhosis could participate if they were
Child-Pugh class A [21].
The NIAID Institutional Review Board approved the
study. All participants provided written informed consent
(NCT01707472). The primary study results are reported
elsewhere [22].
2.2. Transjugular Liver Biopsy with Portal Pressure Measure-
ments. HVPG measurements were obtained during tran-
sjugular liver biopsy. The left, middle, and right hepatic veins
were cannulated and the free hepatic vein pressure (FHVP)
and the wedged hepatic venous pressure (WHVP) were
assessed. TheWHVP was measured within each hepatic vein
branch with gentle inflation of a balloon occlusion catheter.
HVPG was calculated by subtracting the FHVP from the
WHVP. Peak HVPG is reported and used for analysis.
2.3. Histology. Formalin-fixed paraffin-embedded liver bio-
psy sections were stained with hematoxylin and eosin, Mas-
son’s trichrome, or reticulin and interpreted by a single liver
pathologist (DEK). Inflammatory activity and fibrosis were
scored using the modified histology activity index (Ishak)
scoring system [23]. Steatosis was graded on a scale of 0 to
3 based on the percentage of cells with fat according to the
NASH-Clinical Research Network scoring system [24]. Stel-
late cell activation was quantified by immunohistochemical
staining for activated smoothmuscle actin [25] (InovaHealth
Systems, Falls Church, VA).
2.4. Magnetic Resonance Elastography. The imaging proto-
col for magnetic resonance elastography (MRE) has been
described previously [26]. Briefly, MR examination was per-
formed on a 3.0T system (Achieva, Philips Medical Systems,
Best, Netherlands) using 32-element surface coil. A mechan-
ical transducer set at vibration frequency of 56Hz was placed
against the supine subjects’ side at the lowest right rib in
the right-left direction. An operator blinded to participant
clinical status performed image processing to provide shear
wave speed in m/sec.
2.5. Laboratory Markers of Fibrosis. Platelet counts, liver-
associated enzymes including alkaline phosphatase, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and gamma-glutamyl transferase (GGT), and noninvasive
estimators of liver fibrosis validated in similar liver disease
populations, including the APRI [27], FIB-4 [28], Forns [29],
and Fibroindex [30], were determined at the time of liver
biopsy.
2.6. Soluble LOXL2. Soluble LOXL2 (sLOXL2) concentra-
tions were measured in serum using a proprietary immuno-
assay (Singulex, Alameda, CA).
2.7. Hepatic LOXL2 Gene Expression. In a subset of partici-
pants (𝑛 = 12), total RNA isolated from liver was reverse
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transcribed using random primers with the High Capacity
cDNA Reverse Transcriptase Kit (ThermoFischer Scientific,
Waltham,MA), as previously described [22, 31]. Gene expres-
sion was determined as cycle of threshold (Ct) based on
40 PCR cycles, using expression of GAPDH and GUSB as
endogenous controls to determine delta Ct values. GAPDH
Ct values were distributed between 23 and 27. Data from
2 samples was excluded from analysis due to inadequate
signal strength, defined as a GAPDH Ct value >27. Thus,
confirmatory qRT-PCR data are presented from 10 of 12
subjects. Expression reactions using predesigned Taqman
assays assembled into custom-designed 96-well plates (Ther-
moFischer Scientific) were run on an Applied Biosystems
7500 Real-Time PCR System, as previously described [31].
2.8. Statistical Analysis. Pairwise correlations between bio-
markers of interest were evaluated with Spearman’s correla-
tion coefficient. For this exploratory analysis, a 𝑝 value of
≤0.05, without adjustment for multiple comparisons, was
considered statistically significant. Simple linear regression
was employed to screen for biomarkers associated with
HVPG. Biomarkers with a 𝑝 value ≤0.15 from the simple
linear regressions were identified as potential candidates.
Backward stepwise multiple regression analysis was per-
formed on HVPG using the candidate biomarkers. Stepwise
variable elimination was based on a threshold 𝑝 value of
≤0.15. Analyses were performed using JMP v.11 (SAS, Cary,
NC, USA).
2.9. DataAvailability. Datasets analyzed for the current study
are available from the corresponding author on request.
3. Results
3.1. Baseline Demographic and Clinical Characteristics.
Twenty-three patients completed the screening evaluation.
Demographic and clinical characteristics of the cohort are
shown in Table 1. The median age was 57 years (range 45–76
years) and 78% of participants were males. HCV was present
in 18 (78%), 9 of whom had HIV coinfection. Sixteen (89%)
of the HCV-infected participants were genotype 1. Five
(22%) participants had HIV infection and nonalcoholic
steatohepatitis (NASH) [24].
Liver biopsy size ranged from 6 to 24mm,median 12mm.
Six (26%) of samples were <10mm and therefore considered
suboptimal for staging and grading [32].
Median Ishak fibrosis score was 4 (range 1–6) and 11
participants (48%) had cirrhosis, all Child-Pugh class A.
Median HVPGwas 8mmHg (range 3–16mmHg) andHVPG
was ≥10mmHg in 8 (35%) participants.
3.2. Correlates of HVPG. HVPG (𝑛 = 23) correlated positi-
vely with AST (𝑟 = 0.48, 𝑝 = 0.01) and GGT (𝑟 = 0.62, 𝑝 =
0.001) and negatively correlatedwith platelets (𝑟 = −0.72,𝑝 =
0.002). No significant correlation was seen between HVPG
and ALT (Table 2).
While HVPG correlated with liver biopsy fibrosis score
(𝑟 = 0.52, 𝑝 = 0.04), HVPG demonstrated a better corr-
elation with Forns’ Index (𝑟 = 0.76, 𝑝 < 0.001), Fibroindex
Table 1: Baseline demographic and clinical characteristics of study
subjects (𝑛 = 23).
Parameter
Age, years 54 (45–76)
Male, 𝑛 (%) 18 (78%)
Liver disease etiology, 𝑛 (%)
HCV 9 (39%)
HCV/HIV 9 (39%)
HIV/NASH 5 (22%)
Body mass index, kg/m2 30 (21–46)
>30 kg/m2 (obesity), 𝑛 (%) 12 (52%)
Laboratory studies
Platelets, K/uL 159 (45–284)
Alkaline phosphatase, U/L 107 (51–210)
Aspartate aminotransferase (AST), U/L 56 (22–151)
Alanine aminotransferase (ALT), U/L 77 (30–161)
Total bilirubin, mg/dL 0.8 (0.3–2.3)
Direct bilirubin, mg/dL 0.3 (0.1–1.4)
Gamma-glutamyl transferase (GGT), U/L 150 (19–531)
Albumin, g/dL 4.1 (3.0–5.5)
Prothrombin time (PT), seconds 14.3 (12.3–16.4)
International normalized ratio (INR) 1.1 (0.9–1.3)
Hepatitis C characteristics (𝑛 = 18)
HCV viral load, log 10, IU/mL 6.9 (4.7–7.8)
Hepatitis C genotype, 𝑛 (%)
1a 13 (72)
1b 3 (17)
2 1 (6)
4 1 (6)
MRE shear wave velocity, m/sec (𝑛 = 15) 2.13 (1.25–3.03)
HVPG, mmHg 6 (3–16)
Liver biopsy length, mm 12 (6–24)
<10mm, 𝑛 (%) 6 (26)
Liver biopsy scoring
Fibrosis, Ishak (range 0–6) 4 (1–6)
Inflammation, total HAI (range 0–18) 8 (1–14)
Steatosis (range 0–4) 1 (0–2)
Median, range presented unless otherwise noted.
(𝑟 = 0.75, 𝑝 = 0.001), and APRI (𝑟 = 0.59, 𝑝 = 0.02).
(Table 2).
Stepwise regression analysis, including AST, GGT, plate-
lets, liver biopsy fibrosis score, and MRE, identified MRE
as the only biomarker independently associated with HVPG
(𝑅2 = 0.377, 𝑝 = 0.015).
3.3. Correlates of MRE. MRE was completed in 15 partici-
pants (3 HCV, 7HIV/HCV, and 5HIV/NASH).Median shear
wave velocity was 2.13m/sec (range 1.25–3.03m/sec). MRE
correlated significantly with HVPG (𝑟 = 0.64, 𝑝 = 0.009;
Figure 1), as well as with Ishak fibrosis score (𝑟 = 0.71, 𝑝 =
0.003), total histologic activity index (HAI) inflammation
(𝑟 = 0.64, 𝑝 = 0.01), periportal inflammation (𝑟 = 0.72,
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Table 2: Correlation coefficients (Spearman 𝜌) for selected variables∗.
MRE shear wave velocity HVPG Ishak fibrosis score sLOXL2
MRE shear wave velocity (𝑛 = 15) 0.64 0.71 0.82
HVPG (𝑛 = 23) 0.64 0.53 0.58
Liver biopsy (𝑛 = 23)
Ishak fibrosis score 0.71 0.53 0.31
Total HAI inflammation score 0.64 0.49 0.36 0.30
% alpha smooth muscle actin (𝛼SMA) 0.74 0.50 0.51 0.08
Selected laboratory studies (𝑛 = 23)
Platelets −0.70 −0.72 −0.47 −0.57
Aspartate aminotransferase (AST) 0.74 0.50 0.55 0.70
Alanine aminotransferase (ALT) 0.28 0.13 0.42 0.24
Gamma-glutamyl transferase (GGT) 0.43 0.63 0.56 0.28
Non-invasive fibrosis indices (𝑛 = 23)
APRI 0.81 0.57 0.57 0.72
FIB-4 0.67 0.66 0.44 0.71
Forns’ index 0.71 0.76 0.44 0.60
Fibroindex 0.75 0.75 0.40 0.80
Serum soluble LOXL2 (𝑛 = 23) 0.82 0.58 0.31
Liver LOXL2 (𝑛 = 10) 0.86a 0.69 0.18 0.31
MRE: magnetic resonance elastography; HVPG: hepatic venous pressure gradient; HAI: histologic activity index; APRI: AST/platelet ratio index; LOXL2: lysyl
oxidase-like 2.
aMRE and liver LOXL2 results available for 8 participants.
∗𝑝 values are indicated as follows: Italics, 0.01–0.05; Underlined, 0.001–<0.01; Bold, <0.001.
𝑝 = 0.002), lobular inflammation (𝑟 = 0.8, 𝑝 = 0.002), and
𝛼SMA (𝑟 = 0.70, 𝑝 = 0.008) (Table 2).
Furthermore, MRE had a significant positive correlation
with AST (𝑟 = 0.74, 𝑝 = 0.002) and significant negative corr-
elation with platelets (𝑟 = −0.70, 𝑝 = 0.004). In addition,
MRE had significant correlations with noninvasive fibrosis
biomarkers, including APRI (𝑟 = 0.81, 𝑝 < 0.001), FIB-4
(𝑟 = 0.67, 𝑝 = 0.006), Fibroindex (𝑟 = 0.76, 𝑝 = 0.001), and
Forns’ Index (𝑟 = 0.72, 𝑝 = 0.002). No correlation with ALT
(𝑟 = 0.28,𝑝 = 0.31) or GGT (𝑟 = 0.43,𝑝 = 0.1) was observed.
3.4. Correlates of LOXL2. Soluble LOXL2 (𝑛 = 23) levels
correlated significantly with AST (𝑟 = 0.70, 𝑝 = 0.001) and
negatively with platelets (𝑟 = −0.57, 𝑝 = 0.01) (Table 2).
sLOXL2 also had significant positive correlation with the
noninvasive fibrosis biomarkers, APRI (𝑟 = 0.72, 𝑝 = 0.001),
FIB-4 (𝑟 = 0.71, 𝑝 = 0.001), Fibroindex (𝑟 = 0.80, 𝑝 =<
0.0001), and Forns’ Index (𝑟 = 0.6, 𝑝 = 0.009).
Soluble LOXL2 correlated with HVPG (𝑟 = 0.58, 𝑝 =
0.02) but did not correlate with fibrosis or inflammation by
biopsy.
Liver LOXL2 gene expression, analyzed by PCR in 10
participants, also correlated with HVPG (𝑟 = 0.69, 𝑝 = 0.03)
and HAI total (𝑟 = 0.82, 𝑝 = 0.006), but not with fibrosis
(𝑟 = 0.18, 𝑝 = 0.61).
Serum soluble (𝑛 = 13; 𝑟 = 0.82, 𝑝 < 0.001) and liver
LOXL2 (𝑛 = 8; 𝑟 = 0.82, 𝑝 = 0.03) both had strong correla-
tions with MRE (Figure 1).
4. Discussion
We have demonstrated that hepatic MRE measurement of
shear wave velocity may be a valuable biomarker in assessing
the degree of portal hypertension as measured by HVPG.
Stepwise regression analysis of HVPG on multiple biomark-
ers of interest showed that MRE had an independent asso-
ciation with HVPG, suggesting potential utility of MRE
in detection and monitoring of portal hypertension. Addi-
tionally, our study demonstrates correlations between MRE-
measured hepatic shear wave velocity with other noninvasive
fibrosis biomarkers, including APRI, FIB-4, Fibroindex, and
Forns’ Index, and with sLOXL2 levels, although none of these
markers showed an independent association with HVPG in a
multivariate analysis.
In porcine and canine models of progressive portal
hypertension, liver and spleen stiffness assessed by MRE cor-
related with portal pressure [19, 33]. In a small human study,
MRE was sensitive to pressure when change in volumetric
strain was found after transjugular intrahepatic portosys-
temic shunt (TIPS) placement [34]. This study demonstrated
that percentage change in volumetric strain measurements
before and after TIPS procedure correlated well with pre-
TIPS HVPG. These findings suggest that MRE measures
dynamic, pressure-dependent liver stiffness in addition to
the static components of fibrosis. However, to the best of
our knowledge, our study is the first to identify a strong
correlation between MRE-measured shear wave velocity,
HVPG, and serum soluble LOXL2. This was possible at
highermagnetic field strength (3 T) not used in the previously
mentioned studies. A higher magnetic field is known to
be more sensitive to phase changes that are the backbone
of the MRE readout sequences. Additionally, utilizing 32-
channel coils and mechanical vibrations (instead of acoustic
vibrations)might have added to the robustness and sensitivity
of our methods.
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Figure 1: Significant correlations were seen betweenMRE-measured shear wave velocity, a measure of liver stiffness, and HVPG (a), sLOXL2
(c), and liver LOXL2 (d). sLOXL2 also correlated well with HVPG (b).
MRE shear wave velocity also correlated with hepatic
fibrosis, confirming the findings of earlier MRE studies in
HCV and nonalcoholic fatty liver disease [35–37]. Interest-
ingly, MRE had a strong correlation with histologic inflam-
matory scores and 𝛼SMA in addition to histologic fibrosis,
suggesting that MRE-measured shear wave velocity may
detect hepatic inflammation. Studies have shown hepatic
inflammation can increase liver stiffness irrespective of fibro-
sis [38], although the mechanism is not fully understood.
However, the increase in cellular volume seen with inflam-
mationmay affect the procession of the shear wave as it prop-
agates through the hepatic tissue. The dynamic component
of liver stiffness is affected by change in perfusion that can
be influenced by hepatic inflammation. Moreover, changes
in the mechanical state of cells capable of contraction, such
as vascular smooth muscle cells and activated hepatic stellate
cells in the perisinusoidal spaces, can influence liver stiffness
[39].
A correlation was also seen between 𝛼SMA, a contractile
protein expressed by activated hepatic stellate cells with the
myofibroblast phenotype, and HVPG. 𝛼SMA is increased
in the liver of patients with chronic liver diseases and
correlates with the extent of hepatic fibrosis [40]. In chronic
viral hepatitis, 𝛼SMA also correlates with necroinflammatory
grade, suggesting that hepatocyte necroinflammation drives
hepatic stellate cell activation and subsequent fibrogenesis
[41]. Our observations agree with accumulating evidence
suggesting that stellate cells also regulate liver microcircula-
tion and portal pressure. In animal models of fibrosis, 𝛼SMA
causes cellular contractility through calcium dependent and
independent contractile forces, leading to increased portal
resistance [42]. As fibrosis advances, myofibroblasts are
recruited and impede portal circulation through vasoactive
mediators and interactions with the extracellular matrix [43,
44]. Inhibition of 𝛼SMA with nitric oxide in rat and human
hepatic stellate cells reduces portal pressure by 20% [45].
We also observed a correlation between sLOXL2 levels,
hepatic LOXL2 expression, and portal pressure. In addition
to cross-linking collagen, LOXL2 increases matrix tension,
triggering fibroblasts to covert to contractile myofibroblasts
through activation of hepatic TGF𝛽1 [46, 47]. LOXL2 also
stimulates expression of myofibroblasts grown on collagen
matrices through integrin mediated focal adhesion kinase
activation [48]. As myofibroblasts regulate portal resistance,
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LOXL2 may also contribute to development of portal hyper-
tension. Interestingly, sLOXL2 had themost significant corre-
lationwithMRE compared to other parameters. Longitudinal
studies of hepatic fibrosis, including ongoing trials of sim-
tuzumab inNASH and advanced liver fibrosis, will contribute
to the understanding of the function of LOXL2 in fibrosis
progression and portal hypertension.
Limitations of our study include the cross-sectional
design, small size with limited numbers of patients with
cirrhosis and portal hypertension, and lack of a validation
cohort. Further cross-sectional and longitudinal study in a
larger population of patients with clinically significant portal
hypertension is needed to confirm our findings. Multiple
comparisons were made and, though statistically significant,
many correlations were weak. Additionally, the liver biopsy
samples obtained by transjugular biopsy were small, with
6 (26%) suboptimal for grading, likely resulting in under-
staging and undergrading of fibrosis [32] and potentially
attenuating relationships between biopsy parameters and
noninvasive markers. MRE requires specialized hardware,
usually only available at academic medical centers, and is
limited to patients eligible and tolerant of MR imaging.
Compared to transient elastography and other ultrasound-
based shear wave elastography methods, MRE would be
expected to cost more.
In conclusion, MRE shear wave velocity correlates with
noninvasive biomarkers and was independently associated
with HVPG. Given this, MRE may prove to be a useful non-
invasive measure of disease severity and portal hypertension.
In addition, our study demonstrated the novel correlation of
soluble LOXL2 and hepatic LOXL2 expression with portal
hypertension.
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